Skip to main content
. Author manuscript; available in PMC: 2012 May 31.
Published in final edited form as: Cell Immunol. 2011 May 31;270(2):237–250. doi: 10.1016/j.cellimm.2011.05.015

Fig 5. Combination treatment with desloratadine and nortriptyline does not alter the number of peptide-specific T cells following priming.

Fig 5

SJL/J mice received 3×106 naive PLP139–151-specific TCR transgenic T cells (5B6 T cells) on day -2 prior to PLP139–151 in CFA priming. Groups of 5 mice received either Vehicle, or a combination of desloratadine (3mg/kg) plus nortriptyline (10mg/kg) via gavage on days 0–10 post PLP139–151 sensitization. On day 6 spleens and draining lymph nodes were collected and total cells enumerated for the spleen (A) and the lymph nodes (B). We also determined the number 5B6 effector CD4+ T cells (as determined by CD4+/CD90.1+/CD69+/CD44+) and CD4+ regulatory T cells (as determined by CD4+/CD90.1+/CD25+/FoxP3+) present via gating on singlet, live, CD90.1+ congenic CD4+ T cells within the spleen (C) and the lymph nodes (D). The data is presented as the mean number of cell present from 5 mice per treatment group that were analyzed individually. One representative experiment of two is presented.